Node
METTL2A///METTL2B
(Show all edges with this node)Genes Involved in this Node
Networks including this Node
(Click on a network name to show matched edges)
| GSE10445_top8000 - GSE10445 - SiGN-BN NNSR | MERLION LUNG CANCER STUDY |
| GSE10780_top8000 - GSE10780 - SiGN-BN NNSR | Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue |
| GSE10797_top8000 - GSE10797 - SiGN-BN NNSR | Transcriptomes of breast epithelium and stroma in normal reduction mammoplasty and invasive breast cancer patients. |
| GSE10810_top8000 - GSE10810 - SiGN-BN NNSR | Gene expression signatures in breast cancer distinguish phenotype charact., histological subtypes, and tumor invasivness |
| GSE11121_top8000 - GSE11121 - SiGN-BN NNSR | The humoral immune system has a key prognostic impact in node-negative breast cancer |
| GSE11135_top8000 - GSE11135 - SiGN-BN NNSR | The MILE (Microarray Innovations In LEukemia) study pre-phase |
| GSE11482_top8000 - GSE11482 - SiGN-BN NNSR | Rhabdoid Tumor: Gene Expression Clues to Pathogenesis and Potential Therapeutic Targets |
| GSE11582_top8000 - GSE11582 - SiGN-BN NNSR | Genetic Analysis of Human Traits In-Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines |
| GSE11729_top8000 - GSE11729 - SiGN-BN NNSR | H1299 EGF and Iressa stimulation |
| GSE12093_top8000 - GSE12093 - SiGN-BN NNSR | The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
| GSE12453_top8000 - GSE12453 - SiGN-BN NNSR | Origin and pathogenesis of lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis |
| GSE12460_top8000 - GSE12460 - SiGN-BN NNSR | Expression profiling of neuroblastic tumors |
| GSE12627_top8000 - GSE12627 - SiGN-BN NNSR | Non-supervised hierarchical clustering of gene expression data |
| GSE13009_top8000 - GSE13009 - SiGN-BN NNSR | MCF7 EGF, HRG stimulation |
| GSE13168_top8000 - GSE13168 - SiGN-BN NNSR | Effects of glucocorticoids and Protein Kinase A on growth factor- and 1beta- regulated gene |
| GSE13996_top8000 - GSE13996 - SiGN-BN NNSR | Molecular profiling of classical Hodgkin’s lymphoma tissues |
| GSE14208_top8000 - GSE14208 - SiGN-BN NNSR | Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy |
| GSE14210_top8000 - GSE14210 - SiGN-BN NNSR | Expression data from human endoscopic biopsy samples |
| GSE14764_top8000 - GSE14764 - SiGN-BN NNSR | A Prognostic Gene Expression Index in Ovarian Cancer |
| GSE14879_top8000 - GSE14879 - SiGN-BN NNSR | Gene expression study of anaplastic large cell lymphomas: cellular origin, pathogenesis and relation to Hodgkin lymphoma |
| GSE15395_top8000 - GSE15395 - SiGN-BN NNSR | HCT116 tumor cells treated with a CDK inhibitor |
| GSE15396_top8000 - GSE15396 - SiGN-BN NNSR | Peripheral blood mononuclear, DU145, and HCT116 cells treated with a CDK inhibitor |
| GSE15641_top8000 - GSE15641 - SiGN-BN NNSR | Gene signatures of progression and metastasis in renal cell cancer |
| GSE15765_top8000 - GSE15765 - SiGN-BN NNSR | Identification of cholangiocarcinoma-like gene expression traits in hepatocellular carcinoma |
| GSE15852_top8000 - GSE15852 - SiGN-BN NNSR | Expression data from human breast tumors and their paired normal tissues |
| GSE16391_top8000 - GSE16391 - SiGN-BN NNSR | GGI: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial |
| GSE16446_top8000 - GSE16446 - SiGN-BN NNSR | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| GSE16581_top8000 - GSE16581 - SiGN-BN NNSR | Genomic landscape of meningiomas: gene expression |
| GSE17536_top8000 - GSE17536 - SiGN-BN NNSR | Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients (Moffitt Samples) |
| GSE17537_top8000 - GSE17537 - SiGN-BN NNSR | Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients (VMC Samples) |
| GSE17705_top8000 - GSE17705 - SiGN-BN NNSR | Endocrine Sensitivity Index Validation Dataset |
| GSE17920_top8000 - GSE17920 - SiGN-BN NNSR | Expression data of diagnostic biopsy samples from Hodgkin lymphoma patients |
| GSE18088_top8000 - GSE18088 - SiGN-BN NNSR | Correlation of molecular profiles and clinical outcome of stage UICC II colon cancer patients |
| GSE18497_top8000 - GSE18497 - SiGN-BN NNSR | Diagnosis-relapse in ALL |
| GSE18520_top8000 - GSE18520 - SiGN-BN NNSR | Whole-genome oligonucleotide expression analysis of papillary serous ovarian adenocarcinomas |
| GSE18521_top8000 - GSE18521 - SiGN-BN NNSR | A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor: MAGP2 |
| GSE18728_top8000 - GSE18728 - SiGN-BN NNSR | Expression data from human breast cancers pre and post chemothrapy |
| GSE18842_top8000 - GSE18842 - SiGN-BN NNSR | Gene expression analysis of human lung cancer and control samples |
| GSE18864_top8000 - GSE18864 - SiGN-BN NNSR | Tumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients |
| GSE19069_top8000 - GSE19069 - SiGN-BN NNSR | Molecular signatures in peripheral T-cell lymphoma (PTCL) |
| GSE19188_top8000 - GSE19188 - SiGN-BN NNSR | Expression data for early stage NSCLC |
| GSE19784_top8000 - GSE19784 - SiGN-BN NNSR | Gene expression profiling of multiple myeloma patients included in the HOVON65/GMMG-HD4 trial |
| GSE19804_top8000 - GSE19804 - SiGN-BN NNSR | Genome-wide screening of transcriptional modulation in non-smoking female lung cancer in Taiwan |
| GSE20189_top8000 - GSE20189 - SiGN-BN NNSR | A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma |
| GSE20194_top8000 - GSE20194 - SiGN-BN NNSR | MAQC-II Project: human breast cancer (BR) data set |
| GSE20271_top8000 - GSE20271 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients |
| GSE2034_top8000 - GSE2034 - SiGN-BN NNSR | Breast cancer relapse free survival |
| GSE20916_top8000 - GSE20916 - SiGN-BN NNSR | Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data |
| GSE21050_top8000 - GSE21050 - SiGN-BN NNSR | Expression data from Complex genetics sarcomas (cohort 1 and 2) |
| GSE2113_top8000 - GSE2113 - SiGN-BN NNSR | Plasma cell dyscrasias expression profiles associated with distinct IGH translocations in multiple myeloma |
| GSE21653_top8000 - GSE21653 - SiGN-BN NNSR | A gene expression signature identifies two prognostic subgroups of basal breast cancer |
| GSE22597_top8000 - GSE22597 - SiGN-BN NNSR | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE2294_top8000 - GSE2294 - SiGN-BN NNSR | A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor-Positive Tumors |
| GSE23036_top8000 - GSE23036 - SiGN-BN NNSR | Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma |
| GSE23177_top8000 - GSE23177 - SiGN-BN NNSR | Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. |
| GSE23553_top8000 - GSE23553 - SiGN-BN NNSR | Gene expression changes with induction of in-vitro platinum-resistance in ovarian cancer cell lines. |
| GSE23806_top8000 - GSE23806 - SiGN-BN NNSR | Expression data of glioblastoma stem-like (GS) cell lines, conventional glioma cell lines and primary tumors |
| GSE24185_top8000 - GSE24185 - SiGN-BN NNSR | Gene transcription signature of obesity in breast cancer |
| GSE25055_top8000 - GSE25055 - SiGN-BN NNSR | Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25065_top8000 - GSE25065 - SiGN-BN NNSR | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_top8000 - GSE25066 - SiGN-BN NNSR | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE2549_top8000 - GSE2549 - SiGN-BN NNSR | Malignant pleural mesothelioma |
| GSE2603_top8000 - GSE2603 - SiGN-BN NNSR | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE26599_top8000 - GSE26599 - SiGN-BN NNSR | Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2 overexpressing human mammary epithelial cell lines |
| GSE27562_top8000 - GSE27562 - SiGN-BN NNSR | Expression data from human PBMCs from breast cancer patients and controls |
| GSE28497_top8000 - GSE28497 - SiGN-BN NNSR | New markers for minimal residual disease detection in acute lymphoblastic leukemia |
| GSE29013_top8000 - GSE29013 - SiGN-BN NNSR | Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non-Small-Cell Lung Cancer Patients |
| GSE29598_top8000 - GSE29598 - SiGN-BN NNSR | A Methodology for Utilization of Predictive Genomic Signatures in FFPE Samples |
| GSE30375_top8000 - GSE30375 - SiGN-BN NNSR | Gene expression data from sorted and unsorted primary human acute myeloid leukemia (AML) samples |
| GSE31548_top8000 - GSE31548 - SiGN-BN NNSR | MSKCC-B Primary Lung Cancer Specimens |
| GSE4573_top8000 - GSE4573 - SiGN-BN NNSR | Gene expression signatures for predicting prognosis of squamous cell lung carcinomas |
| GSE5206_top8000 - GSE5206 - SiGN-BN NNSR | Large-scale deployment of embryonic gene programming in human and murine colon cancer: a new target for intervention. |
| GSE5327_top8000 - GSE5327 - SiGN-BN NNSR | Breast cancer relapse free survival and lung metastasis free survival |
| GSE5364_top8000 - GSE5364 - SiGN-BN NNSR | A Precisely Regulated Gene Expression Cassette Potently Modulates Metastasis and Survival in Multiple Solid Cancers |
| GSE5460_top8000 - GSE5460 - SiGN-BN NNSR | Predicting Features of Breast Cancer with Gene Expression Patterns |
| GSE5846_top8000 - GSE5846 - SiGN-BN NNSR | NCI-60 Cancer Cell Line |
| GSE6338_top8000 - GSE6338 - SiGN-BN NNSR | Gene expression analysis of Peripheral T-cell Lymphoma/Unspecified |
| GSE6462_top8000 - GSE6462 - SiGN-BN NNSR | MCF7 dose response |
| GSE6477_top8000 - GSE6477 - SiGN-BN NNSR | Expression data from different stages of plasma cell neoplasm |
| GSE6481_top8000 - GSE6481 - SiGN-BN NNSR | Gene Expression Analysis of Soft Tissue Sarcomas: Characterization & Reclassification of Malignant Fibrous Histiocytoma |
| GSE6791_top8000 - GSE6791 - SiGN-BN NNSR | Gene Expression Profiles of HPV-Positive and -Negative Head/Neck and Cervical Cancers |
| GSE6956_top8000 - GSE6956 - SiGN-BN NNSR | Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men |
| GSE7670_top8000 - GSE7670 - SiGN-BN NNSR | Expression data from Lung cancer |
| GSE7696_top8000 - GSE7696 - SiGN-BN NNSR | Glioblastoma from a homogenous cohort of patients treated within clinical trial |
| GSE7904_top8000 - GSE7904 - SiGN-BN NNSR | Expression data from human breast tissue |
| GSE8835_top8000 - GSE8835 - SiGN-BN NNSR | Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. |
| GSE8894_top8000 - GSE8894 - SiGN-BN NNSR | Prediction of Recurrence-Free Survival in Postoperative NSCLC Patients—a Useful Prospective Clinical Practice |
| GSE9195_top8000 - GSE9195 - SiGN-BN NNSR | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen |
| GSE9750_top8000 - GSE9750 - SiGN-BN NNSR | Identification of gene expression profiles in cervical cancer |
| GSE9843_top8000 - GSE9843 - SiGN-BN NNSR | Gene expression profiling of 91 hepatocellular carcinomas with hepatitis C virus etiology |
| GSE9936_top8000 - GSE9936 - SiGN-BN NNSR | Expression data from human breast cancer cells (MCF-7) coexpressing ERalpha and Erbeta, treated with phytoestrogens |
